Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ974MR)

This product GTTS-WQ974MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ974MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12805MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ12540MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ2280MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ5225MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ6053MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ8034MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ14153MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ638MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 8c10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW